Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Neoplasms of the CNS

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 31 articles: HTML format

Single Articles

August 2023
1. LOHMEIER J, Radbruch H, Brenner W, Hamm B, et al
   Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma Using (18)F-FET PET.
   J Nucl Med. 2023 Aug 31:jnumed.123.265642. doi: 10.2967/jnumed.123.265642.
   PubMed     Abstract available
   
   
   
2. VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al
   PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
   J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738.
   PubMed     Abstract available
   
   
   
3. GUTSCHE R, Lowis C, Ziemons K, Kocher M, et al
   Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET.
   J Nucl Med. 2023 Aug 10:jnumed.123.265725. doi: 10.2967/jnumed.123.265725.
   PubMed     Abstract available
   
   
   
4. ALBERT NL, Nelwan DV, Fleischmann DF, Quach S, et al
   Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma.
   J Nucl Med. 2023 Aug 3:jnumed.122.265247. doi: 10.2967/jnumed.122.265247.
   PubMed     Abstract available
   
   
   June 2023
5. MILOSEVIC A, Styczen H, Grueneisen J, Li Y, et al
   Evaluation of [(68)Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space.
   J Nucl Med. 2023 Jun 29:jnumed.123.265424. doi: 10.2967/jnumed.123.265424.
   PubMed     Abstract available
   
   
   May 2023
6. GALLDIKS N, Langen KJ
   Hybrid (18)F-FET PET and Perfusion MRI to Differentiate Disease Progression from Treatment-Related Changes in Malignant Brain Tumors.
   J Nucl Med. 2023 May 18:265647. doi: 10.2967/jnumed.123.265647.
   PubMed    
   
   
   April 2023
7. GRAEF J, Bluemel S, Brenner W, Amthauer H, et al
   [(177)Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement.
   J Nucl Med. 2023 Apr 28:jnumed.122.264850. doi: 10.2967/jnumed.122.264850.
   PubMed     Abstract available
   
   
   
8. SMITH NJ, Deaton TK, Territo W, Graner B, et al
   Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases.
   J Nucl Med. 2023 Apr 28:jnumed.122.265149. doi: 10.2967/jnumed.122.265149.
   PubMed     Abstract available
   
   
   
9. GALLDIKS N, Lohmann P, Fink GR, Langen KJ, et al
   Amino Acid PET in Neurooncology.
   J Nucl Med. 2023 Apr 13:264859. doi: 10.2967/jnumed.122.264859.
   PubMed     Abstract available
   
   
   December 2022
10. NABAVIZADEH A, Bagley SJ, Doot RK, Ware JB, et al
    Distinguishing Progression from Pseudoprogression in Glioblastoma Using (18)F-Fluciclovine PET.
    J Nucl Med. 2022 Dec 22:jnumed.122.264812. doi: 10.2967/jnumed.122.264812.
    PubMed     Abstract available
    
    
    
11. BAILEY DL, Willowson KP, Harris M, Biggin C, et al
    (64)Cu Treatment Planning and (67)Cu Therapy with Radiolabelled SARTATE ([(64)Cu/(67)Cu]MeCOSAR-Octreotate) in Subjects with Unresectable Multifocal Meningioma - Initial Results for Human Imaging, Safety, Biodistribution and Radiation Dosimetry.
    J Nucl Med. 2022 Dec 2:jnumed.122.264586. doi: 10.2967/jnumed.122.264586.
    PubMed     Abstract available
    
    
    
12. SCHLURMANN T, Waschulzik B, Combs S, Gempt J, et al
    Diagnostic utility of amino acid PET in the differential diagnosis of recurrent brain metastases and treatment-related changes: a meta-analysis.
    J Nucl Med. 2022 Dec 2:jnumed.122.264803. doi: 10.2967/jnumed.122.264803.
    PubMed     Abstract available
    
    
    November 2022
13. KREBS S, Schwartz J, Grommes C, Young RJ, et al
    Detecting CXCR4 expression in meningioma on (68)Ga-Pentixafor PET.
    J Nucl Med. 2022 Nov 10. pii: jnumed.122.265127. doi: 10.2967/jnumed.122.265127.
    PubMed    
    
    
    August 2022
14. SHIN J, Parker MFL, Zhu I, Alanizi A, et al
    Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264284. doi: 10.2967/jnumed.122.264284.
    PubMed     Abstract available
    
    
    April 2022
15. ROSEN J, Ceccon G, Bauer EK, Werner JM, et al
    Cost-effectiveness of (18)F-FET PET for early treatment response assessment in glioma patients following adjuvant temozolomide chemotherapy.
    J Nucl Med. 2022 Apr 14. pii: jnumed.122.263790. doi: 10.2967/jnumed.122.263790.
    PubMed     Abstract available
    
    
    March 2022
16. ZARAGORI T, Verger A
    Reply to Letter to the Editor: "(18)F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study".
    J Nucl Med. 2022 Mar 17. pii: jnumed.122.264035. doi: 10.2967/jnumed.122.264035.
    PubMed    
    
    
    February 2022
17. FORAY C, Barca C, Winkeler A, Wagner S, et al
    Interrogating glioma-associated microglia/macrophage dynamics under CSF-1R therapy with multi-tracer in vivo PET/MR imaging.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263318. doi: 10.2967/jnumed.121.263318.
    PubMed     Abstract available
    
    
    January 2022
18. LANGEN KJ, Mottaghy FM
    Letter to the Editor: "(18)F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study" [J Nucl Med 2022; 63:147-157].
    J Nucl Med. 2022 Jan 27. pii: jnumed.122.263837. doi: 10.2967/jnumed.122.263837.
    PubMed    
    
    
    November 2021
19. NIMMAGADDA S
    Imaging PD-L1 expression in melanoma brain metastases.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263209. doi: 10.2967/jnumed.121.263209.
    PubMed    
    
    
    September 2021
20. NIENHUIS PH, Antunes IF, Glaudemans AWJM, Jalving M, et al
    (18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262368. doi: 10.2967/jnumed.121.262368.
    PubMed     Abstract available
    
    
    August 2021
21. BAG AK, Wing MN, Sabin ND, Hwang SN, et al
    [(11)C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence.
    J Nucl Med. 2021 Aug 26. pii: jnumed.120.261891. doi: 10.2967/jnumed.120.261891.
    PubMed     Abstract available
    
    
    
22. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    PubMed     Abstract available
    
    
    
23. BRENDLE C, Maier C, Bender B, Schittenhelm J, et al
    Impact of (18)F-FET PET/MR on clinical management of brain tumor patients.
    J Nucl Med. 2021 Aug 5. pii: jnumed.121.262051. doi: 10.2967/jnumed.121.262051.
    PubMed     Abstract available
    
    
    July 2021
24. VONKEN EPA, Bruijnen RCG, Snijders TJ, Seute T, et al
    Intra-arterial administration boosts (177)Lu-HA-DOTATATE accumulation in salvage meningioma patients.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262491. doi: 10.2967/jnumed.121.262491.
    PubMed     Abstract available
    
    
    
25. BASHARI WA, Senanayake R, MacFarlane J, Gillett D, et al
    Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas.
    J Nucl Med. 2021;62.
    PubMed     Abstract available
    
    
    May 2021
26. ZARAGORI T, Oster J, Roch V, Hossu G, et al
    (18)F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study.
    J Nucl Med. 2021 May 20. pii: jnumed.120.261545. doi: 10.2967/jnumed.120.261545.
    PubMed     Abstract available
    
    
    
27. COLLET S, Guillamo JS, Berro DH, Chakhoyan A, et al
    Simultaneous mapping of vasculature, hypoxia and proliferation using DSC-MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma.
    J Nucl Med. 2021 May 20. pii: jnumed.120.249524. doi: 10.2967/jnumed.120.249524.
    PubMed     Abstract available
    
    
    January 2021
28. JIMENEZ-FRANCO LD, Glatting G, Prasad V, Weber WA, et al
    Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in (177)Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment.
    J Nucl Med. 2021;62:92-98.
    PubMed     Abstract available
    
    
    November 2020
29. CECCON G, Lohmann P, Werner JM, Tscherpel C, et al
    Early treatment response assessment using (18)F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy.
    J Nucl Med. 2020 Nov 6. pii: jnumed.120.254243. doi: 10.2967/jnumed.120.254243.
    PubMed     Abstract available
    
    
    May 2020
30. KRAMER K, Donzelli M, Nwora E, Pandit-Taskar N, et al
    Assessing Cerebrospinal Fluid Flow Dynamics in Pediatric Patients with Central Nervous System Tumors Treated with Intraventricular Radioimmunotherapy.
    J Nucl Med. 2020;61:662-664.
    PubMed     Abstract available
    
    
    April 2020
31. HERHAUS P, Lipkova J, Lammer F, Yakushev I, et al
    CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma.
    J Nucl Med. 2020 Apr 24. pii: jnumed.120.241703. doi: 10.2967/jnumed.120.241703.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: